Research

Research

Understanding GLP-1 peptides and metabolic research through published science and clinical data.

GLP-1 Peptides: The Science

Glucagon-like peptide-1 (GLP-1) is an incretin hormone naturally produced in the gut. It plays a central role in glucose metabolism, insulin secretion, and appetite regulation. GLP-1 receptor agonists (GLP-1 RAs) are synthetic compounds that mimic and extend the action of this natural hormone.

For a comprehensive overview, see our GLP-1 Peptides Guide.

How GLP-1 Works

GLP-1 is released by L-cells in the small intestine in response to food intake. Its primary actions include:

  • Insulin secretion: GLP-1 stimulates glucose-dependent insulin release from pancreatic beta cells. This means insulin is released when blood glucose is elevated, reducing the risk of hypoglycaemia.
  • Glucagon suppression: GLP-1 reduces glucagon secretion from alpha cells, lowering hepatic glucose output.
  • Gastric emptying: GLP-1 slows gastric emptying, which contributes to reduced postprandial glucose spikes and increased satiety.
  • Appetite regulation: GLP-1 acts on receptors in the hypothalamus and brainstem to reduce appetite and food intake.

The native GLP-1 peptide has a very short half-life (approximately 2 minutes) due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). This limitation drove the development of longer-acting GLP-1 receptor agonists.

Key GLP-1 Receptor Agonists

Semaglutide A modified GLP-1 RA with a half-life of approximately one week. It includes structural modifications (Aib substitution at position 8, C-18 fatty acid chain) that confer DPP-4 resistance and albumin binding. Published research includes the SUSTAIN and PIONEER clinical trial programmes. Read more in our GLP-1 Peptides Guide.

Tirzepatide A dual GIP/GLP-1 receptor agonist. It activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. The SURPASS and SURMOUNT trial programmes have published extensively on its pharmacological profile. Covered in detail in our GLP-1 Peptides Guide.

Liraglutide One of the earlier GLP-1 RAs with a half-life of approximately 13 hours due to albumin binding via a C-16 fatty acid chain. Extensively studied in the LEAD trial programme. See our GLP-1 Peptides Guide for clinical trial data.

Exenatide Based on exendin-4, a GLP-1 analogue originally isolated from Gila monster venom. Available in both twice-daily and once-weekly formulations. Details available in our GLP-1 Peptides Guide.

The peptide research landscape extends well beyond GLP-1 receptor agonists. Our compound pages cover key areas of current research interest:

Tissue Repair and Regeneration

  • BPC-157 - A pentadecapeptide studied for wound healing, gut permeability, and tendon repair. Researchers have observed angiogenic and cytoprotective properties in preclinical models.
  • TB-500 (Thymosin Beta-4) - Studied for actin regulation, cell migration, and cardiac repair. Often discussed alongside BPC-157 in tissue repair research contexts.
  • GHK-Cu - A copper peptide studied for collagen synthesis, wound healing, and dermatological applications.

Metabolic Research

  • Retatrutide - A triple GLP-1/GIP/glucagon agonist generating significant research interest following Phase 2 clinical trial data.
  • MOTS-c - A mitochondrial-derived peptide studied for exercise mimetic effects and metabolic regulation.
  • Tesamorelin - A GHRH analogue approved for HIV-associated lipodystrophy, with broader research into visceral fat reduction.

Growth Hormone Secretagogues

  • CJC-1295/Ipamorelin - A GHRH analogue and ghrelin receptor agonist combination studied for pulsatile GH release and body composition.

Mitochondrial Research

  • SS-31 (Elamipretide) - A mitochondrial-targeted peptide studied for cardiac, renal, and mitochondrial membrane stabilisation.

Research Methodology

Understanding research requires understanding how studies are designed and what their limitations are. Key concepts for reading peptide research:

Study Types

  • Randomised controlled trials (RCTs): The gold standard for evaluating efficacy. Participants are randomly assigned to treatment or control groups.
  • Observational studies: Track outcomes in real-world populations without intervention. Useful for identifying patterns but cannot establish causation.
  • Preclinical studies: Laboratory and animal studies that provide mechanistic insights but cannot be directly extrapolated to humans.
  • Meta-analyses and systematic reviews: Combine data from multiple studies to provide a broader picture of the evidence.

Reading Research Critically

When evaluating published research on GLP-1 peptides, consider:

  1. Sample size: Larger studies generally provide more reliable results.
  2. Study duration: Metabolic outcomes may change over time. Short studies may not capture long-term effects.
  3. Endpoints: What was actually measured? Primary endpoints matter more than secondary or exploratory ones.
  4. Conflicts of interest: Who funded the study? Are the authors affiliated with pharmaceutical companies?
  5. Peer review: Has the research been peer-reviewed and published in a reputable journal?
  6. Replication: Have the findings been confirmed by independent research groups?

Emerging Research Areas

Research into GLP-1 receptor agonists continues to expand beyond metabolic applications. Areas of active investigation include:

  • Neuroprotective effects: Preclinical data suggests GLP-1 RAs may have effects on neuroinflammation and neurodegeneration.
  • Cardiovascular outcomes: Multiple large-scale trials have examined cardiovascular endpoints.
  • Hepatic effects: Research into non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
  • Addiction and reward pathways: Preliminary research into effects on substance use behaviours.
  • Renal outcomes: Emerging data on kidney function and protection.

These areas represent ongoing scientific inquiry. The research is at various stages, from preclinical to large-scale trials, and findings should be interpreted within their appropriate context.

Limitations and Caveats

Research literacy means understanding what we don’t know as much as what we do. Important limitations in the current GLP-1 research landscape include:

  • Most large-scale clinical trials are funded by pharmaceutical manufacturers
  • Long-term safety data beyond 2-5 years is limited for newer agents
  • Individual responses vary significantly
  • Preclinical findings frequently do not translate to clinical outcomes
  • Publication bias may affect the available literature
  • Much of the mechanistic research is in animal models

We encourage community members to hold these limitations in mind when discussing research findings.